MIRM Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
Mirum Pharmaceuticals (MIRM) has shown strong revenue growth, with Q4 revenue of $99.41 million, exceeding estimates. The company expects significant growth in 2025, with projected sales between $420 million and $435 million, indicating continued momentum. However, the stock recently fell 4.4% after missing earnings expectations, despite positive guidance.
Technical Analysis:
The stock is currently oversold, with an RSI of 39.26, suggesting a potential rebound. It is trading near the lower Bollinger Band, indicating possible support. The MACD is bearish, but the pre-market rise of 2.09% could signal short-term positivity.
News Sentiment:
Analysts maintain a Strong Buy rating with a target of $65.29, reflecting confidence. However, insider selling activity is a concern. The stock is near Fibonacci support at 42.51, with resistance at 47.03.
Price Prediction and Recommendation:
Based on the analysis, MIRM is expected to rise to $46.50 next week. However, considering the overall bearish trend, it is advisable to sell into this rally rather than holding for further gains.
MIRM Similar Chart Price Prediction
The price of MIRM is predicted to go up 4.73%, based on the high correlation periods with INSP. The similarity of these two price pattern on the periods is 97.68%.
MIRM
INSP
Up: 4.73%Similarity: 97.68%
MIRM Revenue Forecast
MIRM EPS Forecast
MIRM FAQs
What is MIRM revenue forecast for next quarter？
MIRM Analyst's Forecast
David Lebowitz
Citigroup
Strong Buy
2024-11-13
Price Target
$65 → $68
Upside
+54.83%
Citi analyst David Lebowitz raised the firm's price target on Mirum Pharmaceuticals to $68 from $65 and keeps a Buy rating on the shares. Mirum reported Q3 financial results, handily beating Street estimates based on stronger than expected Livmarli sales, the analyst tells investors in a research note. The firm says that while reimbursement dynamics pulled forward some revenue in the quarter, Livmarli's launch continues to demonstrate encouraging growth and increase its contribution towards total franchise sales.
Brian Skorney
Baird
Buy
2024-11-13
Price Target
$44 → $50
Upside
+13.84%
Mani Foroohar
Leerink Partners
Buy
2024-10-17
Price Target
$47 → $49
Upside
+24.62%
